TAK-272 (imarikiren), a novel renin inhibitor, improves cardiac remodeling and mortality in a murine heart failure model

Tomoya Hara; Satoshi Nishimura; Toshihiro Yamamoto; Yumiko Kajimoto; Keiji Kusumoto; Ray Kanagawa; Shota Ikeda; Tomoyuki Nishimoto

doi:10.1371/journal.pone.0202176

Loading metrics

Open Access

Peer-reviewed

Research Article

TAK-272 (imarikiren), a novel renin inhibitor, improves cardiac remodeling and mortality in a murine heart failure model

Tomoya Hara,

Roles Conceptualization, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft

Affiliation Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Satoshi Nishimura,

Roles Formal analysis, Investigation, Methodology

Affiliation Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Toshihiro Yamamoto,

Roles Formal analysis, Investigation, Methodology

Affiliation Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Yumiko Kajimoto,

Roles Formal analysis, Investigation, Methodology

Affiliation Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Keiji Kusumoto,

Roles Project administration, Supervision

Affiliation Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Ray Kanagawa,

Roles Conceptualization, Project administration, Supervision

Affiliation Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Shota Ikeda,

Roles Conceptualization, Project administration, Supervision, Validation

Affiliation Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Tomoyuki Nishimoto

Roles Conceptualization, Project administration, Supervision, Validation, Writing – review & editing

* E-mail: tomoyuki.nishimoto@takeda.com

Affiliation Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan

http://orcid.org/0000-0002-4898-8949

⨯

TAK-272 (imarikiren), a novel renin inhibitor, improves cardiac remodeling and mortality in a murine heart failure model

Tomoya Hara,
Satoshi Nishimura,
Toshihiro Yamamoto,
Yumiko Kajimoto,
Keiji Kusumoto,
Ray Kanagawa,
Shota Ikeda,
Tomoyuki Nishimoto

Published: August 9, 2018
https://doi.org/10.1371/journal.pone.0202176

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Heart failure
Is the Subject Area "Heart failure" applicable to this article?

Thanks for your feedback.
Genetically modified animals
Is the Subject Area "Genetically modified animals" applicable to this article?

Thanks for your feedback.
Blood plasma
Is the Subject Area "Blood plasma" applicable to this article?

Thanks for your feedback.
Mouse models
Is the Subject Area "Mouse models" applicable to this article?

Thanks for your feedback.
Body weight
Is the Subject Area "Body weight" applicable to this article?

Thanks for your feedback.
Drug administration
Is the Subject Area "Drug administration" applicable to this article?

Thanks for your feedback.
Cardiac hypertrophy
Is the Subject Area "Cardiac hypertrophy" applicable to this article?

Thanks for your feedback.
Renin-angiotensin system
Is the Subject Area "Renin-angiotensin system" applicable to this article?

Thanks for your feedback.